Clostridioides Difficile Infection
📧 Sign up to get email alerts when something new happens for Clostridioides Difficile Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection [Phase 2]
Phase 2 multicenter trial comparing lyophilized sterile fecal filtrate to lyophilized fecal microbiota transplant for recurrent Clostridioid…
-
CLINICAL_TRIALS withdrawal · 2024-05-17Clinical Trial Update: Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
A clinical trial evaluating fidaxomicin for Clostridioides difficile infection has been withdrawn.
-
CLINICAL_TRIALS research · 2024-05-16Clinical Trial Update: Probiotics Administration Via Colonoscopic Spray and Oral Administration in CDAD Patients [NA]
This is a clinical trial update about administering probiotics to patients with Clostridioides difficile infection. The trial investigates c…
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Virus as Treatment of C. Difficile Infection (VISION) [NA]
Clinical trial update for a virus-based therapy intended to treat Clostridioides difficile infection, not yet recruiting at Copenhagen Unive…
-
FDA approval · 2024-01-16FDA Approved: FIDAXOMICIN — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's generic fidaxomicin for the treatment of Clostridioides difficile infection under an ANDA approval.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics [Phase 4]
Phase 4 trial updating oral vancomycin use to prevent recurrent Clostridioides difficile infection in patients on antibiotics.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) [Phase 3]
Phase 3 trial (PRISM4) of CP101 for prevention of recurrent Clostridioides difficile infection has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-01Clinical Trial Update: Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection [Phase 2]
Phase 2 trial update for Penn microbiome therapy targeting recurrent Clostridioides difficile infection; study terminated with results poste…
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects [Phase 3]
Phase 3 safety and pharmacokinetics update for ridinilazole in adolescents; trial terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) [Phase 3]
Phase 3 trial of Microbiota Restoration Therapy for recurrent Clostridioides difficile infection has completed, with results posted in Augus…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection [Phase 2]
Phase 2 trial of VE303 for prevention of recurrent Clostridioides difficile infection has completed; results were posted in 2023.
-
FDA approval · 2023-05-26FDA Approved: ZINPLAVA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZINPLAVA (bezlotoxumab) from Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2023-05-19Clinical Trial Update: Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection [Phase 3]
Phase 3 clinical trial evaluating fecal filtrate as a treatment for recurrent Clostridioides difficile infection is ongoing or not yet repor…
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection [Phase 3]
Phase 3 open-label trial of SER-109 for recurrent Clostridioides difficile infection has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Bezlotoxumab Versus FMT for Multiple Recurrent CDI [Phase 4]
Phase 4 trial comparing bezlotoxumab to FMT for multiple recurrent Clostridioides difficile infection was withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection [Phase 3]
Phase 3 trial comparing ridinilazole to vancomycin for Clostridioides difficile infection has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants [Phase 2]
A Phase 2 clinical trial evaluating the safety and immunogenicity of the Boostrix vaccine in pregnant Malian women and their infants, with r…
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age [Phase 3]
Phase 3 trial update evaluating lot consistency of a Clostridium difficile vaccine in healthy adults 65-85 years old; results posted after c…
-
FDA approval · 2022-11-14FDA Approved: VANCOMYCIN HYDROCHLORIDE — Original Application (Ascend Laboratories, LLC)
FDA approved the original application for vancomycin hydrochloride (generic) by Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff [Phase 2]
Phase 2 trial evaluating oral Full-Spectrum Microbiota (CP101) for efficacy, safety, and tolerability in recurrent Clostridioides difficile …
-
CLINICAL_TRIALS research · 2022-03-14Clinical Trial Update: Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection [NA]
Clinical trial update on pulsed UV xenon disinfection aimed at preventing healthcare-associated infections and Clostridium difficile infecti…
-
FDA approval · 2022-02-16FDA Approved: VANCOMYCIN HYDROCHLORIDE FOR ORAL SOLUTION — Supplemental Application (Wilshire Pharmaceuticals, Inc.)
FDA approved a supplemental application for vancomycin hydrochloride for oral solution, authorizing its oral formulation. The product is man…
-
FDA approval · 2021-11-18FDA Approved: VANCOMYCIN HYDROCHLORIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approved vancomycin hydrochloride as a generic drug under an Original Application from Slate Run Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation [Phase 2]
Phase 2 trial investigating gut recolonization by fecal transplantation for recurrent Clostridioides difficile infection completed with resu…
-
FDA approval · 2021-01-29FDA Approved: VANCOMYCIN HYDROCHLORIDE FOR ORAL SOLUTION — Supplemental Application (Wilshire Pharmaceuticals, Inc.)
FDA approved a supplemental application to approve vancomycin hydrochloride for oral solution, expanding its use for treating Clostridioides…